Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results and Limited Review Report
Date of Board Meeting / Approval: 30th July, 2026 (Meeting time: 02:00 pm to 04:40 pm)
Audit Opinion: Clean opinion with no qualifications
Auditor's Comment: The limited review report contains an emphasis of matter regarding the amalgamation of J.B. Chemicals & Pharmaceuticals Limited, but the conclusion is not modified.
Key Financial Highlights [₹ in crores]
Standalone Results:
Revenue from Operations: ₹4,158 crore (Q1 FY27) vs ₹2,616 crore (Q1 FY26) - 58.7% YoY growth
Total Income: ₹4,137 crore (Q1 FY27) vs ₹2,611 crore (Q1 FY26)
Net Profit: ₹492 crore (Q1 FY27) vs ₹551 crore (Q1 FY26) - 10.7% decline
EPS: Basic and Diluted ₹12.94 (Face value of ₹5 each)
Other Equity: ₹17,754 crore (as at 30-Jun-2026)
Debt: Paid-up debt capital ₹11,390 crore
Consolidated Results:
Revenue from Operations: ₹4,921 crore (Q1 FY27) vs ₹3,178 crore (Q1 FY26) - 54.8% YoY growth
Total Income: ₹4,909 crore (Q1 FY27) vs ₹3,141 crore (Q1 FY26)
Net Profit: ₹566 crore attributable to owners (Q1 FY27) vs ₹548 crore (Q1 FY26) - 3.3% growth
EPS: Basic and Diluted ₹14.87 (Face value of ₹5 each)
Other Equity: ₹17,848 crore (as at 30-Jun-2026)
Debt: Paid-up debt capital ₹11,390 crore
Segment-wise Performance:
The Company operates in a single segment - Generic Formulation Business
Regional Performance (Consolidated):
- India: ₹2,890 crore (60% growth YoY)
- International: ₹1,919 crore (57% growth YoY)
- Others: ₹112 crore (-24% growth YoY)
Business Division Performance:
- Base Business: ₹3,720 crore (17% growth YoY) with Op. EBITDA* ₹1,240 crore (33.3% margin)
- JB Business: ₹1,201 crore (10% growth) with Op. EBITDA* ₹424 crore (35.3% margin)
Corporate Actions:
Amalgamation Completed: J.B. Chemicals & Pharmaceuticals Limited amalgamated with Torrent Pharmaceuticals effective from appointed date 21st January, 2026. NCLT approval received on 6th July, 2026, filed with ROC on 8th July, 2026.
Share Allotment: On 20th July, 2026, the Company allotted 4,19,22,416 fully paid-up equity shares of ₹5 each to eligible shareholders of JB Pharma in share exchange ratio of 51:100 (Torrent:JB Pharma).
Other Significant Information:
Accounting Treatment: The amalgamation has been accounted using pooling of interest method with effect from appointed date 21st January, 2026. Comparative financial information has been restated.
Stamp Duty: Financial results do not include effect of stamp duty payable in respect of Scheme of Amalgamation, pending adjudication by appropriate authority.
R&D Spend: ₹172 crore (4% of revenue), up 10% YoY
Geographic Performance Highlights:
- India: Ranked 1st in IPM cardiac market; Gx Semaglutide recorded 36% market share
- Brazil: Revenue ₹277 crore, up 27%; 58 products under ANVISA review
- US: Revenue ₹418 crore, up 36%; constant currency growth 23%
- Germany: Revenue ₹318 crore, up 3%; impacted by supply disruption